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Abstract
Background: Although APOBEC3G protein is a potent and innate anti-HIV-1 cellular factor, HIV-
1 Vif counteracts the effect of APOBEC3G by promoting its degradation through proteasome-
mediated proteolysis. Thus, any means that could prevent APOBEC3G degradation could
potentially enhance its anti-viral effect. The UBA2 domain has been identified as an intrinsic
stabilization signal that protects protein from proteasomal degradation. In this pilot study, we
tested whether APOBEC3G, when it is fused with UBA2, can resist Vif-mediated proteasomal
degradation and further inhibit HIV-1 infection.
Results: APOBEC3G-UBA2 fusion protein is indeed more resistant to Vif-mediated degradation
than APOBEC3G. The ability of UBA2 domain to stabilize APOBEC3G was diminished when
polyubiquitin was over-expressed and the APOBEC3G-UBA2 fusion protein was found to bind less
polyubiquitin than APOBEC3G, suggesting that UBA2 stabilizes APOBEC3G by preventing
ubiquitin chain elongation and proteasome-mediated proteolysis. Consistently, treatment of cells
with a proteasome inhibitor MG132 alleviated protein degradation of APOBEC3G and
APOBEC3G-UBA2 fusion proteins. Analysis of the effect of APOBEC3G-UBA2 fusion protein on
viral infectivity indicated that infection of virus packaged from HEK293 cells expressing
APOBEC3G-UBA2 fusion protein is significantly lower than those packaged from HEK293 cells
over-producing APOBEC3G or APOBEC3G-UBA2 mutant fusion proteins.
Conclusion: Fusion of UBA2 to APOBEC3G can make it more difficult to be degraded by
proteasome. Thus, UBA2 could potentially be used to antagonize Vif-mediated APOBEC3G
degradation by preventing polyubiquitination. The stabilized APOBEC3G-UBA2 fusion protein
gives stronger inhibitory effect on viral infectivity than APOBEC3G without UBA2.
Background
There is an active and antagonistic host-pathogen interac-
tion during HIV-1 infection. Upon infection by HIV-1,
host cells react with various innate, cellular and humoral
immune responses to counteract the viral invasion. Lim-
ited and transient restriction of viral infection is normally
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responses through various counteracting actions. For
example, APOBEC3G (apolipoprotein B mRNA-editing
enzyme catalytic polypeptide-like 3G), a host innate anti-
viral protein [1], was found to be responsible for the inhi-
bition of Vif-minus-HIV-1 infection [2]; whereas Vif
counteracts this host cellular response by promoting pro-
teasome-mediated degradation of APOBEC3G [3].
APOBEC3G is a member of cellular cytidine deaminase
family. At the late phase of viral life cycle, APOBEC3G is
encapsided into the virus particles through interaction
with viral Gag protein [4-8]. Specifically, N-terminal
domain of APOBEC3G is known to be important for tar-
geting the protein to viral nucleoprotein complex and
confers antiviral activity [9]. Once a virus enters a new cell,
virus genomic RNA will be reverse transcribed into cDNA
before integrating into the host cellular chromosome
DNA. As part of the host innate immune responses,
APOBEC3G prevents viral cDNA synthesis by deaminat-
ing deoxycytidines (dC) in the minus-strand retroviral
cDNA replication intermediate [10-14]. As result, it cre-
ates stop codons or G-A transitions in the newly synthe-
sized viral cDNA that is subjective to elimination by host
DNA repair machinery [12,14]. As part of the viral coun-
teracting effort, HIV-1 Vif counteracts this innate host cel-
lular defense by promoting its degradation through
proteasome-mediated proteolysis [3,15-18]. Specifically,
Vif recruits Cullin5-EloB/C E3 ligase to induce polyubiq-
uitination of APOBEC3G [19,20]. Specifically, Vif uses a
viral SOCX-box to recruit EloB/C [12] and a HCCH motif
to recruit Cullin 5 [21]. By eliminating APOBEC3G from
the cytoplasm, Vif prevents APOBEC3G from packaging
into the viral particles thus augment HIV-1 infection in
"non-permissive" cells [2]. Based on the Vif-APOBEC3G
antagonism at the protein level, it is conceivable that cre-
ation of proteolysis-resistant APOBEC3G could poten-
tially strengthen the host innate anti-viral response and
further inhibit HIV-1 infection. The objective of this pilot
study was to test this premise.
Ubiquitin-associated domain 2 (UBA2) is typically 45
amino acids long that specifically bind to both mono- and
polyubiquitins [22]. Homonuclear NMR spectroscopy
revealed that UBA2 domain contains a low resolution
structure composed of three α-helices folded around a
hydrophobic core [23], suggesting that UBA2 domain
may be involved in multiple functions. Indeed, functions
of UBA2 have been linked to protein ubiquitination, UV
excision repair, and cell signaling [24]. For example,
UBA2 domain is found in a family of protein including
human HHR23A, budding yeast Rad23 and fission yeast
Rhp23 [22,25]. All of the HHR23A homologues are com-
posed of an N-terminal ubiquitin-like (UBL) domain and
two ubiquitin-associated (UBA) domains, i.e., an internal
UBA1 domain and a C-terminal UBA2 domain [22].
HHR23A interacts with 26S proteasome through its N-ter-
minal UBL domain to promote protein degradation [26-
28]. UBA domains bind to ubiquitin [29-31] and play a
role in targeting ubiquitinated substrates to the proteas-
ome [32-34]. As a general rule, ubiquitination of proteins
and subsequent recruitment of ubiquitinated proteins to
the proteasome always results in rapid degradation of
those proteins [35]. However, binding of HHR23A or
Rad23 to ubiquitin and proteasome does not lead to their
degradation [26,36]. It was believed that there must be a
specific domain in the HHR23A or its homologous pro-
teins that serve as a protective "stabilization signal" and
prevents them from proteasome-mediated proteolysis
[37]. Indeed, UBA2 domain was recently found to func-
tion as a cis-acting and transferable "stabilization signal"
[35]. This "stabilization signal" can be destroyed simply
by introducing a point mutation at residue 392 (L392A)
of the UBA2 domain [35].
Since Vif promotes APOBEC3G degradation through pro-
teasome-mediated proteolysis of ubiquitinated proteins,
and because UBA2 decreases protein degradation through
this pathway, we hypothesize that UBA2, if fused with
APOBEC3G, should be able to act as a "stabilization sig-
nal" and to protect APOBEC3G from Vif-mediated degra-
dation. Here we tested this hypothesis by comparing
protein stability of normal APOBEC3G protein with the
APOBEC3G-UBA2 fusion proteins in the presence of Vif.
To gain additional functional insights into the molecular
mechanism underlying the ability of UBA2 to prevent
protein degradation, the effects of UBA2 on APOBEC3G
protein degradation under the conditions of excessive
polyubiquitination or the lack of proteasome activity were
examined. The effect of UBA2 on APOBEC3G stability
and its impact on viral infectivity was also investigated.
Results
APOBEC3G fused with UBA2 is more resistant to Vif-
mediated protein degradation than APOBEC3G
To test whether UBA2 can stabilize APOBEC3G protein,
UBA2 was fused at the C-terminal end of APOBEC3G (Fig.
1A). The APOBEC3G without the UBA2 fusion (Fig. 1B)
or fused with a mutant L392A UBA2 that is incapable of
stabilizing proteins (Fig. 1C; [35]), was used as controls.
The fusion products were cloned into a mammalian gene
expression plasmid pCDNA3.1 and the resulting plasmids
were designated as pcDNA3.1(-)-Apo-E/Hygromycin (E)
for the untagged APOBEC3G, pcDNA3.1(-)-Apo-U/
Hygromycin (U) for the APOBEC3G-UBA2 fusion, and
pcDNA3.1(-)-Apo-M/Hygromycin (M) for the
APOBEC3G-UBA2* mutant fusion. Protein stability of
APOBEC3G was determined either by expression of these
plasmids individually or by co-transfection of each indi-
vidual APOBEC3G-carrying plasmid construct with a Vif-Page 2 of 13
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in Fig. 2A, expression of untagged APOBEC3G produced a
strong protein band at approx. 46 kD consistent with the
size of APOBEC3G (Fig. 2A, lane 2). Slight increase in
molecular weight was detected in the APOBEC3G-UBA2
and APOBEC3G-UBA2* fusion products (Fig. 2A, lanes
3–4).
Approximately equal amount of protein was produced in
each of these plasmid constructs without vif gene expres-
sion (Fig. 2A–b). When vif is expressed in the APOBEC3G-
producing HEK293 cells, a significant decrease of
APOBEC3G with more than 10-fold reduction was
noticed in the untagged APOBEC3G cells (Fig. 2A, lane 5).
In contrast, a small with about 2-fold decease of
APOBEC3G-UBA was detected when APOBEC3G was
fused with the wild type UBA2 (Fig. 2A, lane 6). Consist-
ent with the finding that a single point mutation of
APOBEC3G (L392A) abolishes the ability of APOBEC3G
to stabilize proteins [35], production of Vif in these cells
reduced the APOBEC3G-UBA2* protein level to the level
that is similar to the untagged APOBEC3G (Fig. 2A lane 7
vs. lane 5). Together, these data suggested that the wild
type UBA2, when it is fused with APOBEC3G, is indeed
able to stabilize APOBEC3G and renders it more resistant
to Vif than the untagged APOBEC3G.
One possibility for the observed resistance of APOBEC3G-
UBA2 to Vif could be explained by the reduced binding of
APOBEC3G-UBA2 to Vif. To test this possibility, Myc-
tagged Vif was pull-down by immunoprecipitation in the
APOBEC3G-producing HEK293 cells. Western blot analy-
ses were carried out to measure the bindings of different
APOBEC3G constructs to Vif. As shown in Fig. 2B, no
obvious reduction of the binding of APOBEC3G-UBA2 to
Vif was observed (Fig. 2B, lane 5). In fact, binding of
Schematic drawings of the APOBEC3G-carrying plasmidsFigure 1
Schematic drawings of the APOBEC3G-carrying plasmids. E: untagged APOBEC3G-carrying plasmid (pcDNA3.1(-)-
Apo-E/Hygromycin); U: same plasmid but contains an in-frame fusion of UB2A with APOBEC3G (pcDNA3.1(-)-Apo-U/Hygro-
mycin); M: same as U but contains an in-frame fusion of a mutated UBA2* with APOBEC3G (pcDNA3.1(-)-Apo-M/Hygromy-
cin). The asterisk * by UBA2 indicates location of a single point mutation in the UBA2 domain (L392A) that renders it incapable 
of stabilizing proteins [35]. PCMV, CMV promoter; the single letter restriction enzyme designations are: X, XhoI; E, EcoRI; H, 
HindIII.Page 3 of 13
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APOBEC3G fused with UBA2 domain is more resistant to Vif-mediated degradation than APOBEC3GFigure 2
APOBEC3G fused with UBA2 domain is more resistant to Vif-mediated degradation than APOBEC3G. A-a. 
HEK293 cells, which is APOBEC3G-negative, was co-transfected with 1.5 μg of Vif-carrying plasmid (Vif-VR1012) DNA and 6 
μg of plasmid DNA that expresses untagged APOBEC3G (E), APOBEC3G-UBA2 (U) fusion protein or APOBEC3G-UBA2* 
mutant fusion protein (M), respectively. Forty-five hours post-transfection (p.t.), cell lysates were subject to SDS polyacrylad-
mide gel electrophoresis and analyzed by Western blot analysis using monoclonal anti-APOBEC3G and anti-Vif antibodies. 
Level of protein loading was measured by anti-β-actin antibody. A-b. The intensity of APOBEC3G protein was determined by 
densitometry. Value of the relative intensity of APOBEC3G was calculated in relative to the untagged APOBEC3G (E) and 
adjusted based on the relative intensity of β-actin in each lane to that of the control (C). B. UBA2 fusion to APOBEC3G does 
not affect its binding to Vif. Myc-tagged Vif was pulled-down in different APOBEC3G-producing HEK293 cells by immunopre-
cipitation using anti-Myc antibody. Binding of different forms of APOBEC3G to Vif was detected by using anti-APOBEC3G and 
anti-Vif antibodies, respectively. SUP, supernatants; IP, immunoprecipitation.
Retrovirology 2008, 5:72 http://www.retrovirology.com/content/5/1/72APOBEC3G-UBA2 to Vif appeared to be stronger than the
untagged APOBEC3G or APOBEC3G with the mutated
UBA2. This increase binding could potentially be due to
presence of the excessive APOBEC3G-UBA2, which is
clearly shown by the high level of APOBEC3G remained
in the supernatant (Fig. 2B, lane 2). Nevertheless, these
data suggest that the observed resistance of APOBEC3G to
Vif is not caused by reduction binding.
Overexpression of polyubiquitin diminishes the ability of 
UBA2 to stabilize APOBEC3G against Vif
Most cellular proteins are targeted for degradation by the
proteasome. Prior to proteasome-mediated proteolysis,
the proteins are covalently attached to ubiquitin. A poly-
ubiquitin chain will be formed and function as a degrada-
tion signal. The poly-ubiquitinated protein can then be
recognized by the 26S proteasome for degradation [38]. If
the ubiquitin chain elongation is interrupted, this protein
cannot be recognized by the 26 S proteasome and thus it
cannot be degraded. UBA2 binds to ubiquitin directly and
inhibits elongation of polyubiquitin chains by capping
conjugated ubiquitin [30,39]. Since Vif mediates
APOBEC3G degradation by promoting protein ubiquiti-
nation of APOBEC3G [3]via Cullin5-EloB/C E3 ligase to
induce polyubiquitination of APOBEC3G [19,20], it is
possible that UBA2 may either sequester ubiquitin from
APOBEC3G or prevent polyubiquitin chain elongation.
As results, the un-ubiquitinated APOBEC3G becomes
resistant to proteasome-mediated proteolysis. To test this
possibility, polyubiquitin was overproduced through a
pcDNA3.1-HA-Ubiquitin plasmid [40,41] in the HEK293
cells co-producing Vif and various APOBEC3G products.
As shown in Fig. 3A, APOBEC3G-UBA2 fusion protein
showed relative strong intensity in comparison with the
untagged APOBEC3G (Fig. 3A–a, lane 3 vs. lane 1). How-
ever, production of excessive polyubiquitin completely
abolished the difference between the protein level of
APOBEC3G-UBA2 and APOBEC3G (Fig. 3A–a, lane 5 vs.
lane 4). Western protein blotting with anti-Vif and anti-
HA for ubiquitin detection confirmed proper production
of Vif and polyubiquitin in these cells. Therefore, over-
production of polyubiquitin can diminish the ability of
UBA2 for APOBEC3G stabilization.
To further verify whether fusion of APOBEC3G to UBA2
results in less binding to polyubiquitin, APOBEC3G in the
presence or absence of Vif was collected by immunopre-
cipitation using anti-APOBEC3G monoclonal antibody.
The pull-down protein products were subject to Western
blot analyses as shown in Fig. 3B. Approximately equal
amount of APOBEC3G was collected in all cells with the
exception of the control cells (Fig. 3B–a, lane 4), in which
only endogenous APOBEC3G was pull-down. Without
Vif, minimal and background level of polyubiquitin was
detected in all APOBEC3G-producing cells (Fig. 3B–a,
lanes 1–3). In contrast, strong polyubiquitin was detected
in the vif-expressing cells with untagged APOBEC3G or
APOBEC3G-UBA2* (Fig. 3B–a, lanes 5 and 7). However,
much reduced level of polyubiquitination was observed
in vif-expressing cells carrying the APOBEC3G-UBA2 (Fig.
3B–a, lane 6). This observation provides direct support to
the notion that UBA2 may prevent polyubiquitin chain
elongation on APOBEC3G.
Treatment of HEK293 cells with proteasome inhibitor 
MG132 alleviated degradation of APOBEC3G and 
APOBEC3G-UBA2 fusion proteins
To test whether inhibition of the 26S proteasome activity
has any impact on the ability of UBA2 to stabilize
APOBEC3G against Vif, APOBEC3G-producing HEK293
cells were treated the proteasome inhibitor MG132 in the
presence of Vif. APOBEC3G protein levels were measured
and compared between cells with or without the MG132
treatment. Similar to what we have shown in Fig. 2A, the
protein intensity of APOBEC3G-UBA2 was significantly
higher than that without the UBA2 tag (Fig. 4A, lane 2 vs.
lane 1), suggesting the protein stabilizing capacity of
UBA2. APOBEC3G fusion with a mutant UBA2* reduced
its ability to stabilize APOBEC3G (Fig. 4A, lane 3). Signif-
icantly, HEK293 cells treated with the proteasome inhibi-
tor MG132 all showed much higher protein intensities
than the APOBEC3G-UBA2 producing cells without
MG132 treatment (Fig. 4A, lanes 4–6 vs. lane 2). These
enhanced protein levels were observed in all of the
APOBEC3G protein constructs regardless whether it is
fused with UBA2 or not, suggesting UBA2 stabilizes
APOBEC3G through resistance to proteasome-mediated
proteolysis.
Viruses packaged from cells expressing APOBEC3G-UBA2 
fusion protein gives stronger suppressive effect on viral 
infectivity than that packed from APOBEC3G
To test whether APOBEC3G stabilized by UBA2 can fur-
ther enhance the suppressive effect of APOBEC3G on viral
infectivity, the HIV-1 viral particles were produced from
HEK293 cells that expressing different constructs of
APOBEC3G as described. To minimize potential differ-
ences of production of each protein construct and viral
packaging, HEK293 cells that stably express APOBEC3G,
APOBEC3G-UBA2, and APOBEC3G-UBA2* fusion pro-
teins were created by proper antibiotic selection. High
level expression of these proteins was further verified by
Western blot analysis (Figure 5A–a). To produce
APOBEC3G-carrying viral particles, the pNL4-3 plasmid
was expressed in HEK293 viral producing cells that stably
expressing different APOBEC3G fusion proteins. The
infectious viral particles were harvested 48 hrs after trans-
fection as previously described [42]. Presence of different
APOBEC3G constructs was detected with approx. equal
amount within all three types of viral particles (Fig. 5A–Page 5 of 13
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Fusion of UBA2 to APOBEC3G limits its polyubiquitinationigure 3
Fusion of UBA2 to APOBEC3G limits its polyubiquitination. A-a, Expression of polyubiquitin abolishes the ability of 
UBA2 to stabilize APOBEC3G. HEK293 cells were co-transfected as described in Fig. 2. In addition, 3 μg of a plasmid DNA 
(pcDNA3.1-HA-Ubiquitin) that produces polyubiquitin [40,41] was also co-transfected to HEK293 cells. Western blot analysis 
was carried out by using monoclonal anti-APOBEC3G, anti-Vif, anti-HA, and anti-β-actin antibodies respectively. A-b. The 
intensity of APOBEC3G protein and value of the relative intensity of APOBEC3G was determined as described in Fig. 2. Note, 
a protein band that migrates with similar size to APOBEC3G-UBA2 as shown in lane E sometimes react to anti- APOBEC3G 
antibody. This is a non-specific protein band because it only reacts to certain batches of anti-APOBEC3G antibody. To elimi-
nate this background, the protein intensity of APOBEC3G-UBA2 and APOBEC3G-UBA2* was calculated by subtracting the 
level of this non-specific protein. B. Fusion of UBA2 to APOBEC3G shows reduced polyubiquitination. B-a, Vif protein was 
pull-down in different APOBEC3G-producing HEK293 cells by immunoprecipitation using anti-Vif antibody. Binding of high 
molecular weight of ubiquitin (polyubiquitin) to Vif was detected by using anti-ubiquitin antibody. B-b, the relative intensity of 
ubiquitin to β-actin control was determined by densitometry. Also note that there are not much protein level differences of 
APOBEC3G between lane 2 (U) and lane 3 (M). This is likely due to the fact that more protein is loaded in lane 3 than lane 2 
as shown by the relative protein levels of β-actin.
Retrovirology 2008, 5:72 http://www.retrovirology.com/content/5/1/72b). To test whether the potential effect of the viral express-
ing Vif on the stability of APOBEC3G, levels of
APOBEC3G in the viral particle producing HEK293 cells
were further measured after viral gene expressions. Essen-
tially the same Vif effect on APOBEC3G was seen between
the viral expressing Vif and Vif expressed from a plasmid
(Fig. 5A–c).
To test the potential impact of different APOBEC3G con-
structs packaged in the viral particles on viral infectivity
and replication, concentration of the viral stocks were
normalized by determination of the p24 antigen levels.
The viral infectivity of viruses packaged with different
APOBEC3G constructs were measured with the MAGI-
CCR5 assay as previously described [43]. This assay meas-
ures viral infectivity in a single cycle of viral infection.
About 50% reduction of viral infectivity was observed in
viruses packed from cells producing high level of
APOBEC3G than endogenous level of APOBEC3G (Fig.
5B–a, lane E vs. lane C). An additional 17% and signifi-
cant reduction of viral infectivity (P < 0.01) was also
observed in viruses packaged from cells expressing the
APOBEC3G-UBA2 fusion protein (Fig. 5B–a, lane U). In
contrast, no significant difference was detected between
viruses carrying untagged APOBEC3G or APOBEC3G
fused with a mutant UBA2, indicating the additional
reduction of viral infectivity observed in the APOBEC3G-
UBA2 fusion was indeed due to the stabilizing effect of
UBA2 on APOBEC3G (Fig. 5B–a, lane M vs. lane E). These
differences in viral infectivity were not observed in the
Vif(-) viral infections suggesting the observed differences
were caused by Vif (Fig. 5B–b).
To further evaluate the observed effects of APOBEC3G
variants on spread viral infection, CEM-SS cells, a cell line
derived from CD4-positive T-lymphocytes, were infected
with the same Vif(+) and Vif(-) viral particles packaged
with different APOBEC3G variants as described above.
P24 antigenemia was measured from day 3 to day 21 post-
viral infection. Similar suppressive effects of the
APOBEC3G variant on viral infection as described above
for the MAGI-CCR5 experiment were also seen in CEM-SS
cells (Fig. 5C). The differences are however most pro-
nounced in day 21 post-infection: while infection of
CEM-SS with the control viral particles produced approx-
imately 1,200 ng/ml of p24 antigen, about 400 ng/ml of
p24 antigen was seen in CEM-SS cells infected with viral
particles packed with either untagged APOBEC3G or the
UBA2 mutant variant (Fig. 5C–a). Additional reduction of
viral replication with approx. 200 ng/ml was observed in
the same cells when they were infected with the viral par-
ticles packaged with the APOBEC3G-UBA2. All of the
APOBEC3G variants conferred the same level of strong
viral suppression against Vif(-) viral infection (Fig. 5C–b),
suggesting that the observed differences as described in
the Vif(+) viral infections were due to interaction between
Vif and APOBEC3G.
Discussion
In this report we demonstrated, proof of principle, a plau-
sible strategy that could be used to stabilize APOBEC3G
and to further reduce viral infection. Consistent with a
previous study [44], we first confirmed that virus pack-
aged from the HEK293 cells expressing high level of
APOBEC3G gives stronger suppressive effect on viral
infectivity than the virus that was packaged from normal
cells (Fig. 5B, lane C vs. E). Moreover, we showed that
APOBEC3G protein, when it is fused with an ubiquitin-
associated domain, i.e., UBA2, becomes more resistant to
Vif-mediated protein degradation (Fig. 2A). Importantly,
additional suppression of viral infectivity or replication
was found in the APOBEC3G-UBA2-carrying virus in
comparison with the APOBEC3G-carrying virus without
the UBA2 fusion (Fig. 5B–C). The observed suppression of
APOBEC3G-UBA2 on viral infection was diminished in
Vif(-) viral infections suggesting that the observed
APOBEC3G-UBA2 effect was due to its interaction with
Vif. Interestingly, despite its resistance of APOBEC3G-
UBA2 to Vif-induced degradation, APOBEC3G-UBA2 is
packaged at essentially the same level into wild type HIV-
1 virions as untagged APOBEC3G or APOBEC3G tagged
with mutant UBA2 (Fig. 5). This observation seems to
argue against the dogma that Vif prevents packaging of
APOBEC3G by inducing its proteasomal degradation.
Moreover, the wild type HIV-1 produced in the presence
of APOBEC3G-UBA2 appeared to be more infectious than
the Vif(-) mutant (Fig. 5B a–b [U]). This finding could
potentially be even more significant than the reduction in
infectivity of the wild type virus "E" vs. "U" as shown in
Fig. 5Ba, as it may indicate that Vif may confer suppressive
effect on APOBEC3G. in addition to the degradation
effect. Indeed, a recent report by Opi et al. [45] showed
that inhibition of viral infectivity by a degradation-resist-
ant form of APOBEC3G is still sensitive to Vif. Together
these data suggest that stabilized APOBEC3G by UBA2
may have contributed to the observed viral suppression.
This premise is certainly supported by our observation
that the same virus that carries APOBEC3G fused with a
mutant UBA2 lost its suppressive effect on viral infectivity
(Fig. 5B–C).
It should be mentioned that the observed suppressive
effect of APOBEC3G-UBA2 on viral infection is not as pro-
nounced as the suppressive effect observed in an
APOBEC3G D128K mutant, in which the D128K mutant
inhibits HIV-1 by several hundred fold [46,47]. One pos-
sible explanation of the discrepancy between our study
and that of the cited APOBEC3G D128K study might be
due to the difference in binding of Vif to these APOPEC3G
variants. For example, Vif still bind to APOBEC3G-UBA2Page 7 of 13
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mutant [46,47].
The molecular mechanism underlying the ability of UBA2
to stabilize APOBEC3G needs to be further delineated.
There are three possibilities that could potentially explain
the observed stabilizing effect of UBA2 on APOBEC3G
based on the published reports and data presented here.
First, similar to the finding described in the budding yeast
homologue (Rad23) of HHR23A [48], UBA2 prevents
Rad23 protein degradation by binding to the UBL domain
at its N-terminal end where the 26S proteasome attaches
[35,49]. Following the same scenario, binding of UBA2 to
the 26S proteasome-binding site could conceivably pro-
tect APOBEC3G from proteasome-mediated degradation.
However, this possibility is unlikely because there is no
UBL domain or alike which thus thus far been identified
in APOBEC3G. Second, C-terminal fusion of UBA2 to
APOBEC3G may stabilize APOBEC3G by hindering it
from unfolding by the 19S regulatory subunit of the pro-
teasome, a scenario that has been described previously
[35]. Prior to proteasome-mediated degradation of a pro-
tein, 19S regulatory subunit of proteasome must first
unfold the polyubiquitinated protein as subsequent deg-
radation requires an unstructured initiation site of the
unfolded protein [50]. An early in vitro study showed that
tightly folded C-terminal domains can block protein
unfolding and thus delay proteasomal degradation [51].
It is possible that fusion of UBA2 with APOBEC3G created
a tightly folded C-terminal end of protein that block
APOBEC3G-UBA2 unfolding and proteasomal degrada-
tion. If this is the case, addition of excessive ubiquitin or
inhibition of proteasome activity should not affect the
level of protein observed. Therefore, this possibility
should be excluded. Third, UBA2 prevents polyubiquiti-
nation of APOBEC3G the same way as described for other
proteins [48,52]. UBA2 inhibits elongation of polyubiqui-
tin chains by capping conjugated ubiquitin [30,39]. Prior
to proteasome-mediated proteolysis, the protein destined
to be degraded is first polyubiquitined. If the ubiquitin
chain elongation is somehow restricted, this protein can-
not be recognized by the 26 S proteasome and thus it can-
not be degraded. To a certain extent, our results seem to
support this possibility because when excessive polyubiq-
uitin were produced, it abolishes the ability of UBA2 to
stabilize APOBEC3G (Fig. 3A). Furthermore, our data
showed APOBEC3G-UBA2 bound less polyubiquitin than
the other APOBEC3G variants (Fig. 3B). Nevertheless,
should UBA2 indeed stabilized APOBEC3G through this
mechanism, the stabilization to proteasome-mediated
proteolysis by UBA2 is not complete because the 26S pro-
teasome is still able to degrade part of the APOBEC3G-
UBA2 protein. This was certainly supported by the obser-
vation that inhibition of the 26S proteasome activity by
MG132 resulted in further increase of the APOBEC3G-
UBA2 level (Fig. 4A, lane U). In order to further explore
the potential ability of UBA2 to stabilize APOBEC3G,
future experiments could include testing of different
UBA2 constructs isolated from various species such as
budding or fission yeast. Alternatively, multiple and tan-
dem UBA2 could potentially be used to test whether they
can provide stronger stabilizing effect on APOBEC3G
than a single UBA2. Additionally, it should be pointed out
that introduction of therapeutic APOBEC3G-UBA2 into
human cells, through whatever technique, will not elimi-
nate preexisting endogenous (untagged) APOBEC3G.
Such APOBEC3G could tie up Vif and minimize degrada-
tion-independent activities of Vif thus making
APOBEC3G-UBA2 more effective. This possibility can cer-
tainly be tested by co-expression of tagged and untagged
APOBEC3G.
Treatment of HEK293 cells with proteasome inhibitor MG132 alleviates degradation of APOBEC3G and APOBEC3G-UBA2 fusion proteinsFigure 4
Treatment of HEK293 cells with proteasome inhibi-
tor MG132 alleviates degradation of APOBEC3G and 
APOBEC3G-UBA2 fusion proteins. HEK293 cells were 
co-transfected as described in Fig. 2. Transfected cells were 
treated with 2.5 mM of the proteasome inhibitor MG132 27 
hrs p.t. Western blot analysis was carried out as described in 
Fig. 3. B. The intensity of APOBEC3G protein and the value 
of the relative intensity of APOBEC3G were calculated the 
same way as described in Fig. 2.Page 8 of 13
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APOBEC3G fused with UBA2 confers stronger suppressive effect on viral infectivity than APOBEC3GFigure 5
APOBEC3G fused with UBA2 confers stronger suppressive effect on viral infectivity than APOBEC3G. A. Pack-
aging of different APOBEC3G variants into HIV-1 viral particles from HEK293 cells that stably express high level of 
APOBEC3G, APOBEC3G-UBA2 or APOBEC3G-UBA2*. a, The HEK293 cells that stably producing high level of APOBEC3G, 
APOBEC3G-UBA2 or APOBEC3G-UBA2* were established by selection of hygromycin resistant cells (300 μg/ml) for 2 weeks 
and verified by the Western blot analyses; b, Different APOBEC3G variants were equally packaged into the HIV-1 viral parti-
cles and harvested from HEK293 cells by expressing pNL4-3 plasmid in the control HEK293 cells lack of APOBEC3G (C) or 
HEK293 cells stably expressing different APOBEC3G variants; c, effect of viral expressing Vif on protein degradation of 
APOBEC3G variants. B. Effect of APOBEC3G variants on viral infectivity in MAGI-CCR5 cells. The MAGI-CCR5 cells were 
infected with viral supernatants harvested from the HEK293 cells that stably produce either no APOBEC3G or high level of dif-
ferent APOBEC3G constructs. Forty-eight hours post-infection, cells were stained by β-galactosidase for HIV-infected cells as 
described previously [43]. The viral infectivity of APOBEC3G-negative control HEK293 cells (C) was calibrated to 100% for 
comparison purpose. The viral infectivity was determined by comparing the total number of blue cells with the total number of 
cells counted. Data shown represent average of three independent experiments. Error Bars shown are standard errors of the 
means. a. results of wild type Vif(+) HIV-1NL4-3 infection; b. results of Vif(-) HIV-1NL4-3ΔVif infection. * p < 0.01. C. Effect of 
APOBEC3G variants on spread viral infection in CEM-SS cells. CEM-SS cells expressing APOBEC3G(E), APOBEC3G-UBA2(U), 
or APOBEC3G-UBA2(M) was infected by Vif(+) or Vif(-) HIV-1NL4-3. P24 antigen was measured post-infected day 3, 5, 7, 10 14, 
21. a. results of wild type Vif(+) HIV-1NL4-3 infection; b. results of Vif(-) HIV-1NL4-3 Δ Vif infection.
Retrovirology 2008, 5:72 http://www.retrovirology.com/content/5/1/72Conclusion
This is a proof of concept study that provides, for the first
time, evidence showing APOBEC3G, when it is stabilized
by UBA2, attenuates HIV-1 infectivity. Further refinement
of this strategy is needed to develop a more efficient way
to stabilize APOBEC3G. It nevertheless promises a new
and testable approach in that it may contribute to future
strategies against HIV infection.
Methods
Cell lines and Plasmids
HEK293 cell was maintained in Dulbecco's minimal
essential medium (DMEM) supplemented with 10% fetal
bovine serum. MAGI-CCR5 cell, a HeLa-CD4 cell deriva-
tive that expresses CCR5 and that has an integrated copy
of the HIV-1 long terminal repeat (LTR)-driven β-D-galac-
tosidase reporter gene [43], was maintained in Dulbecco's
modified Eagle's medium (DMEM) supplied with 10%
(vol/vol) fetal bovine serum (FBS) (Bio Whittaker), 200
μg/ml G418, 50 U/ml hygromycin (CalBiochem), and 1
μg/ml puromycin. CEM-SS cells were grown in RPMI
1640 medium. To produce APOBEC3G, APOBEC3G-
UBA2, and APOBEC3G-mutant UBA2 fusion proteins,
three plasmids including pcDNA3.1(-)-Apo-E/Hygromy-
cin (E), pcDNA3.1(-)-Apo-U/Hygromycin (U), and
pcDNA3.1(-)-Apo-M/Hygromycin (M) were constructed
according to the strategy shown in Figure 1. To make these
plasmid constructs, the APOBEC3G gene was amplified
from the plasmid pcDNA3.1-HA-APOBEC3G by PCR. The
5' primer used for the construction of all three plasmids
was 5'-GCGCGCGCGCCTCGAGACCATGAAGCCT-
CACTT-3'; The 3' primers used for the construction of the
E plasmid was 5'-ATCCAAGACGGAATTCCTA-
GAACTCGTTTTCCTGATTCTGGAG-3' and the 3' primer
used for the U and M plasmid was 5'-ATCCAAGACG-
GAATTCGTTTTCCTGATTCTGGAG-3'. The UBA2 gene
fragment was amplified from plasmid pcDNA3.1-
HHR23A by PCR. The 5' primer used was 5'-
ATCCAAGACGGAATTCACGCCGCAGGAGAAA-
GAAGCTATAG-3'; the 3' primer for the APOPEC3G-UBA2
fusion was 5'-ATCGTACTCGAAGCTTCTAACTCAGGAG-
GAAGTTGGCAG-3'; and the 3' primer for the
APOPEC3G-UBA2* fusion was 5'-ATCGTACTCGAAGCT-
TCTAACTCAGagcGAAGTTGGCAG-3'. Purified PCR prod-
ucts were first cloned into the mammalian expression
plasmid pcDNA3.1(-)/neo, the gene fragments were then
cut off and cloned into a pcDNA3.1(-)/Hygromycin plas-
mid. Correct insertion and nucleotide sequence of each
gene fragment was verified by restriction enzyme diges-
tions and was confirmed by nucleotide sequencing. The
pcDNA3.1-HA-Ubiquitin plasmid was used to express
polyubiquitin [40,41]. The pNL4-3 plasmid was used to
packaged virus in HEK293 cells as described previously
[42].
Immunoprecipitation and immunoblot analysis
Transfected HEK293 cells were harvested, washed 2 times
with cold PBS, and lysed in lysis buffer (50 mM Tris, pH
7.5, with 150 mM NaCl, 1% Triton X-100, and complete
protease inhibitor cocktail tablets) at 4°C for 1 h, then
centrifuged at 10,000 g for 30 min. Cell lysates were
mixed with anti-APOBEC3G Ab (NIH reagents program)
and incubated at 4°C for overnight. The mixture of anti-
gen and antibody was incubated with protein A agarose
beads (Sigma) and incubated at 4°C for 3 h. Samples were
then washed three times with washing buffer (20 mM Tris,
pH 7.5, with 100 mM NaCl, 0.1 mM EDTA, and 0.05%
Tween-20). Beads were eluted with loading buffer. The
eluted materials were then analyzed by SDS-PAGE.
For Western blot analysis, HEK293 cells were harvested
and rinsed with ice-cold HEPES-buffered saline (pH 7.0),
then lysed in an ice-cold cell lysis buffer [20 mM Tris-HCl,
pH7.6, 150 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40,
1 mM DTT, 5 μM Trichostatin A, 1 mM sodium
orthovanadate, 1 mM PMSF, 1 mM NaF and complete
protease inhibitors (Roche Applied Science)]. Cellular
lysates were prepared and the protein concentration was
determined using the Pierce protein assay kit. For immu-
noblotting, an aliquot of total lysate (50 μg of proteins) in
2 × SDS-PAGE sample buffer (1:1 v/v) was electro-
phoresed and transferred to a nitrocellulose filter. Filters
were incubated with appropriate primary antibody in Tris-
buffered saline (TBS, pH 7.5) and 5% skim milk or 5%
BSA overnight. The primary antibodies include anti-
APOBEC3G antibody at a 1:500 dilution (NIH reagents
program), anti-Vif antibody at a 1:200 dilution (NIH rea-
gents program), anti-HA antibody at a 1:1000 dilution,
and anti-β-actin (Sigma) antibody at a 1:3,000 dilution.
After washing, the filter was further incubated with sec-
ondary antibody in TBS-Tween-20 (TBS-T) buffer for 1 h.
Protein bands were visualized by an ECL detection sys-
tem. Goat anti-mouse or anti-mouse IgG-HRP conjugate
(dilution of 1:3,000) were used as secondary antibodies
according to the corresponding primary antibodies.
Transfection and Viral Packaging
Plasmid DNA was transfected into HEK293 or CEM-SS
cells by using Lipofectamine 2000 transfection reagent
(Invitrogen) according to the manufacturer's instructions.
To create stable APOBEC3G-expressing cell lines, the plas-
mid DNA of pcDNA3.1(-)-Apo-E/Hygromycin,
pcDNA3.1(-)-Apo-U/Hygromycin, pcDNA3.1(-)-Apo-M/
Hygromycin was transfected into HEK293 cells. HEK293
cells that stably produce a high level of APOBEC3G,
APOBEC3G-UBA2 or APOBEC3G-UBA2* were first estab-
lished by selection of hygromycin resistant cells (300 μg/
ml) for 2 weeks and verified by the Western blot analyses
(Fig. 5A–a). To generate infectious viral particles, HEK293
was inoculated into 6-well plate one day before pNL4-3Page 10 of 13
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confluency. The full-length molecular clone pNL4-3 and
pNL4-3 ΔVif plasmid was then transfected into HEK293
cells to produce wild type Vif(+) or mutant Vif(-) HIV-1
viruses [42]. Forty-eight hours p.t., HIV-1 viral particles
were harvested from the supernatants of HEK293 cells by
centrifugation at 1,000 rpm/min for 5 min. The isolated
viral particles were split into 2 ml aliquots and stored in -
80°C. To ensure equal levels of viral infection, the viral
stocks were normalized by determining levels of p24 anti-
gens in each viral stock. The level of p24 antigen was
determined by using a commercial p24 antigen kit from
ZeptoMetrix Co. (Buffalo, NY) following the manufac-
ture's instructions.
Viral infections
To evaluate the suppressive effect of APOBEC3G,
APOBEC3G-UBA2 and APOBEC3G-UBA2* on viral repli-
cation in proliferating CD4+ T-lymphocytes, CEM-SS cells
(APOBEC3G negative CD4+ T-lymphocytes) that stably
express a plasmid control, APOBEC3G, APOBEC3G-
UBA2 and APOBEC3G-UBA2* were established. 1 × 106
CEM-SS cells were either mock infected or infected with
3000 TCID50 of HIV-1NL4-3 and HIV-1NL4-3ΔVif. The viral
replication was measured by p24 antigenemia.
MAGI assay
MAGI assay was used to determine the viral infectivity as
previously described [43]. Briefly, MAGI-CCR5 cells were
cultured in 6-well plates one day before infection so that
cells can reach approximately 40–50% confluency on the
day of infection. The medium of each well was removed
before the viral supernatant was added to infect cells in a
total volume of 300 μl of complete DMEM with 20 μg/ml
of DEAE-dextran. Cells in virus-containing medium were
incubated at 37°C in a 5% CO2 incubator. After 2 hours
incubation, 1.5 ml complete DMEM medium was added
to each well. The cells were further incubated under the
same condition for 48 hrs after incubation. The media
were removed and 2 ml fixing solution (1% formalde-
hyde, 0.2% glutaraldehyde in PBS) was added to each
well. Cells were washed twice with PBS and then fixed for
5 min. with 600 μl of staining solution (20 μl of 0.2 M
potassium ferrocyanide, 20 μl of 0.2 M potassium ferricy-
anide, 2 μl of 1 M MgCl2, 10 μl of 40 mg/ml X-gal in PBS).
Cells were then incubated for 2 hrs at 37°C in a non-CO2
incubator. Staining was stopped by removing the staining
solution and washed twice with PBS. Blue dots were
counted as infected cells as described previously [43]
under the microscope. The viral infectivity was deter-
mined by comparing the total number of infected cells
with uninfected cells in each well. Each experiment was
performed in triplicate and results of these experiments
were repeated at least three times. Statistic student t-test
was used to determine potential significant difference
among different treatment groups.
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